Migraine drug rimegepant under Real-World review in greater bay area

NCT ID NCT06221267

Completed Knowledge-focused Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed registry study followed 120 migraine patients in the Guangdong-Hong Kong-Macao Greater Bay Area who were prescribed rimegepant by their doctors. The goal was to see how the drug affects their quality of life, daily functioning, work productivity, and overall satisfaction in a real-world setting. Researchers collected data using standard questionnaires but did not give any treatment or change how patients used the medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rimegepant
What this could lead to: If successful, this study could provide real-world evidence on how rimegepant improves quality of life and daily functioning for migraine patients.
What could go wrong: This is an observational registry study, not a controlled trial, so results may be influenced by patient selection or other factors. It does not test new effectiveness or safety beyond what is already known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Locations

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, 510120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.